Sana Biotechnology

### Executive Summary Sana Biotechnology raised $117.8M in a Regulation D private placement, with first sale on 2025-10-12. The filing lists Andreessen Horowitz and Sands Capital as related persons, signaling strong institutional backing for its synthetic biology and intracellular mRNA delivery platform. ### Investor Edge Watch for a subsequent D/A amendment or a Series D round announcement, which would indicate capital growth or terms changes. Also monitor for any public filings or press releases regarding clinical trial progress or IP licensing. ### Sector capital positioning This large private raise in synthetic biology and mRNA delivery signals sustained capital flow into next-generation genetic medicine platforms, even amid a cautious public biotech market. ### Convergence Signals No direct public signals (patents, contracts, legislation) are evident from this filing. However, the involvement of top-tier VCs suggests potential upcoming clinical milestones or platform partnerships. ### Key Takeaways - Sana Biotechnology raised $117.8M in a private placement, with Andreessen Horowitz and Sands Capital as related persons. - The raise targets synthetic biology and intracellular mRNA delivery, a high-growth sector. - First sale date is listed as 2025-10-12, which is after today's date—this may be a data entry error or forward-looking statement. ### Risk Indicators & Flags The first sale date (2025-10-12) is in the future relative to the filing date, which is atypical and may indicate a data error or a pre-arranged future closing. No D/A amendments are present, but this could be an initial filing with terms yet to be finalized. ### Verification & References Filing is a Form D (initial notice) with SEC accession 0001702600-24-20047. Verify at SEC EDGAR: https://www.sec.gov/cgi-bin/browse-edgar?company=Sana%20Biotechnology&type=D&action=getcompany. First sale date 2025-10-12 is in the future relative to today (2026-06-02), which is unusual and should be double-checked.